专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO00062787A1 METHODS AND COMPOSITIONS FOR USE IN POTENTIATING ANTIGEN PRESENTATION BY ANTIGEN PRESENTING CELLS 审中-公开
标题翻译：用于抗原呈递细胞抗原呈递的方法和组合物
公开(公告)号：WO00062787A1
公开(公告)日：2000-10-26
申请号：PCT/US2000/009664
申请日：2000-04-11
IPC分类号： A61K39/00 , A61K39/39 , C12N5/071 , C12N5/0781 , C12N5/0786 , A61K35/00 , A01N1/02 , A61K48/00 , C12N15/63 , C12N15/85 , C12N15/86
CPC分类号： A61K31/711 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/5152 , A61K2039/5154 , A61K2039/55561 , C12N5/0635 , C12N5/0645 , C12N5/0648 , C12N2501/056
摘要： The invention provides methods to enhance the antigen-presentation capabilities of cells capable of antigen presentation by contacting the cells with an immunostimulatory oligonucleotide. Through such contact, treated antigen presenting cells are induced to take up antigen (through upregulation of Fc R expression), present antigen (through upregulation of MHC Class I and II as well as CD1d expression), produce co-stimulatory factors (B7 and CD40), provide cell-to-cell adhesion (through upregulation of ICAM expression) and increase Th1 stimulatory cytokine production (e.g., IL-12), all at levels greater than are achieved through contact of the antigen presenting cells with antigen alone. Methods for use of the enhanced antigen presenting cells to activate T cells to respond to antigen are also provided, as are compositions of antigen presenting cells with activity enhanced according to the invention.
摘要翻译：本发明提供了通过使细胞与免疫刺激性寡核苷酸接触来增强能够产生抗原呈递的细胞的抗原呈递能力的方法。通过这种接触，诱导处理的抗原呈递细胞摄取抗原（通过上调Fc R表达），呈递抗原（通过上调MHC I类和II类以及CD1d表达），产生共刺激因子（B7和CD40 ），提供细胞间细胞粘附（通过上调ICAM表达）并增加Th1刺激细胞因子产生（例如IL-12），所有这些都大于通过抗原呈递细胞与抗原单独接触而实现的。还提供了使用增强的抗原呈递细胞激活T细胞以应答抗原的方法，以及根据本发明增强活性的抗原呈递细胞的组合物。

32. 发明申请

WO99051248A1 NEW COMBINED PREPARATION FOR THE TREATMENT OF NEOPLASIC DISEASES OR OF INFECTIOUS DISEASES 审中-公开
标题翻译：用于治疗神经疾病或感染性疾病的新型组合制剂
公开(公告)号：WO99051248A1
公开(公告)日：1999-10-14
申请号：PCT/EP1999/002105
申请日：1999-03-29
IPC分类号： C12N5/00 , A61K35/14 , A61K35/15 , A61K38/00 , A61K39/00 , A61K45/00 , A61P31/00 , A61P35/00 , C12N5/0786 , C12N5/08
CPC分类号： C12N5/0645 , A61K31/232 , A61K31/282 , A61K31/336 , A61K31/407 , A61K31/505 , A61K31/655 , A61K31/704 , A61K35/15 , A61K39/0011 , A61K45/06 , A61K2039/5154 , A61K2300/00
摘要： The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.
摘要翻译：本发明涉及包含作为活性物质的以下单独组分的组合制剂，其为成套工具：单核细胞来源的细胞，特别是细胞毒性巨噬细胞，化学疗法或免疫治疗药物，用于同时，分开或顺序使用，用于治疗癌症或传染病。

33. 发明申请

WO1998014783A1 GRANULOCYTIC AND MONOCYTIC DIFFERENTIATION OF CD34hi CELLS ASSOCIATED WITH DISTINCT CHANGES IN THE EXPRESSION OF THE PU.1 REGULATED MOLECULES, CD64 AND M-CSFR 审中-公开
标题翻译：与表达PU.1调节分子，CD64和M-CSFR相关的不同变化相关的CD34细胞的颗粒细胞和单核细胞差异
公开(公告)号：WO1998014783A1
公开(公告)日：1998-04-09
申请号：PCT/US1997017453
申请日：1997-09-29
申请人： BECTON DICKINSON AND COMPANY
发明人： BECTON DICKINSON AND COMPANY , OLWEUS, Johanna , LUND-JOHANSEN, Fridtjof , THOMPSON, Peter
IPC分类号： G01N33/53
CPC分类号： C12N5/0645 , C12N5/0642 , C12N2501/125 , C12N2501/14 , C12N2501/22 , C12N2501/23 , G01N33/56972
摘要： The present invention demonstrates that M-CSF responsiveness and the M-CSFR expression can be used to discriminate monocytic and granulocytic cells within a population of cells which strongly expresses the CD34 antigen (CD34 ). Briefly, the method comprises isolating phenotypically and functionally defined CD34 subsets, and staining with anti-M-CSFR monoclonal antibodies to measure expression on these primitive progenitors and cells committed to the granulocytic and monocytic lineages, based upon expression of M-CSFR. CD34 M-CSFR cells are highly clonogenic and approximately 70 % of the colonies are CFU-M (monocytic), whereas less than 20 % were CFU-G (granulocytic). In contrast, CD34 cells that were positive for the granulo-monocytic marker CD64 and negative for the M-CSFR contained high frequencies of 91 % pure CFU-Gs. After 60h in culture, CD34 M-CSFR cells developed into distinct populations of M-CSFR and M-CSFR cells. These two populations gave rise almost exclusively to monocytes and granulocytes, respectively. This result demonstrates that M-CSF target specificity among human hematopoietic progenitor cells is determined by lineage-specific regulation of the M-CSFR and demonstrate that M-CSFR is a useful marker to discriminate CFU-Ms from CFU-Gs.
摘要翻译：本发明证实M-CSF响应性和M-CSFR表达可用于区分强烈表达CD34抗原（CD34ζ）的细胞群体内的单核细胞和粒细胞。简而言之，该方法包括分离表型和功能定义的CD34 +亚型，并用抗M-CSFR单克隆抗体染色，以测量基于M-CSFR表达的这些原始祖细胞和致粒细胞和单核细胞谱系的细胞的表达。 CD34细胞是高度克隆的，大约70％的菌落是CFU-M（单核细胞），而小于20％是CFU-G（粒细胞）。相比之下，对于粒细胞单核细胞标志物CD64呈阳性且M-CSFR阴性的CD34细胞含有91％纯CFU-Gs的高频率。培养60小时后，将CD34M-CSFR细胞发育成M-CSFR和M-CSFR细胞的不同群体。这两个群体几乎分别产生单核细胞和粒细胞。该结果表明，通过M-CSFR的谱系特异性调节来确定人造血祖细胞中的M-CSF靶特异性，并证明M-CSFR是鉴别CFU-Ms与CFU-Gs的有用标记。

34. 发明申请

WO1997032992A1 IMMORTALIZED HEMATOPOIETIC CELL LINES, CELL SYSTEM THEREOF WITH STROMAL CELLS, IN VITRO, EX VIVO AND IN VIVO USES, AND IN VITRO GENERATION OF DENDRITIC CELLS AND MACROPHAGES 审中-公开
标题翻译：重组细胞细胞系，细胞系，细胞系，细胞体外，体外和体内用途，以及细胞和巨噬细胞的生成
公开(公告)号：WO1997032992A1
公开(公告)日：1997-09-12
申请号：PCT/US1997003186
申请日：1997-03-07
申请人： AMBA BIOSCIENCES, L.L.C.
发明人： AMBA BIOSCIENCES, L.L.C. , GOPAL, T., Venkat
IPC分类号： C12N15/87
CPC分类号： C12N5/0669 , C12N5/0639 , C12N5/0645 , C12N5/0647 , C12N15/87 , C12N2501/125 , C12N2501/22 , C12N2501/23 , C12N2501/25 , C12N2502/1394 , C12N2510/04 , G01N33/5014
摘要： Extented life hematopoietic cell lines include stromal cell lines useful for the in vitro maintenance of undifferentiated pluripotent hematopoietic stem cells. Undifferentiated and differentiated immortalized stem cells are suitable for bone marrow transplantation, gene therapy and cell therapy applications, and as an in vitro model system for drug discovery and toxicological testing.
摘要翻译：延伸的生命造血细胞系包括可用于体外维持未分化多能造血干细胞的基质细胞系。未分化和分化的永生化干细胞适用于骨髓移植，基因治疗和细胞治疗应用，以及作为药物发现和毒理学测试的体外模型系统。

35. 发明申请

WO1996001045A1 METHOD AND SYSTEM FOR CULTIVATING CELLS PARTICULARLY MACROPHAGES 审中-公开
标题翻译：用于培养细胞特异性MACROPHAGES的方法和系统
公开(公告)号：WO1996001045A1
公开(公告)日：1996-01-18
申请号：PCT/US1995008351
申请日：1995-06-30
申请人： CROTTY, Daphna , DANON, David
发明人： CROTTY, Daphna
IPC分类号： A01N01/02
CPC分类号： C12N5/0645 , A61K2035/124 , C12M29/26 , C12M37/04
摘要： A method of cultivating cells present in suspension by placing the cells, one or more reagents, and a culture medium in separate sterile containers connected together and hermetically sealed by sterile tubings having fluid flow control devices which may be manually opened and closed, and opening and closing the fluid flow control devices as required in order to transfer the contents of one container to another, while isolating the container contents from the external environment. The method is particularly useful for cultivating macrophages in a completely controlled atmosphere hermetically sealed from the outside atmosphere.
摘要翻译：通过将细胞，一种或多种试剂和培养基放置在连接在一起的分开的无菌容器中并通过无菌管道密封的方法来培养悬浮液中的细胞，所述无菌管具有可手动打开和关闭的流体流动控制装置，根据需要关闭流体流量控制装置，以便将容器内容物与外部环境隔离，从而将一个容器的内容物传送到另一容器。该方法对于在与外界气氛密封的完全控制的气氛中培养巨噬细胞特别有用。

36. 发明申请

WO2016207257A1 CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM 审中-公开
标题翻译：细致有针对性的成分递送系统
公开(公告)号：WO2016207257A1
公开(公告)日：2016-12-29
申请号：PCT/EP2016/064484
申请日：2016-06-22
申请人： CELLIS SP. Z O.O. [LTD.]
发明人： KRÓL, Magdalena , BENNI, Irene , BAIOCCO, Paola , RYGIEL, Tomasz , BOFFI, Alberto
IPC分类号： C12N5/0786 , A61K38/42 , A61K47/48 , A61K35/15
CPC分类号： C12N5/0645 , A61K35/15 , A61K38/40 , A61K38/42 , A61K47/64 , A61K47/644 , A61K47/6445 , A61K47/6901 , A61K51/1203 , C12N5/0636 , C12N5/0642
摘要： The present invention relates to an isolated cellular targeted delivery system comprising a CD45 + leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.
摘要翻译：本发明涉及一种分离的细胞靶向递送系统，其包含CD45 +白细胞细胞，其在所述细胞内包含一种或多种铁结合蛋白和活性成分的复合物，以及用于产生这种分离的细胞靶向递送系统的方法和该系统的用途用于治疗，特别是用于治疗癌症。

37. 发明申请

WO2016207256A1 CELLULAR TARGETED LABEL DELIVERY SYSTEM 审中-公开
标题翻译：细致的标签传送系统
公开(公告)号：WO2016207256A1
公开(公告)日：2016-12-29
申请号：PCT/EP2016/064483
申请日：2016-06-22
申请人： CELLIS SP. Z O.O. [LTD.]
发明人： KRÓL, Magdalena , BENNI, Irene , BAIOCCO, Paola , RYGIEL, Tomasz , BOFFI, Alberto
IPC分类号： C12N5/0786 , A61K38/42 , A61K47/48 , A61K35/15 , G01N33/50
CPC分类号： C12N5/0645 , A61K35/15 , A61K38/40 , A61K38/42 , A61K47/64 , A61K47/644 , A61K47/6445 , A61K47/6901 , A61K51/1203 , C12N5/0636 , C12N5/0642
摘要： The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.
摘要翻译：本发明涉及一种分离的细胞靶向递送系统，其包含CD45 +白细胞细胞，其在所述细胞内包含一种或多种铁结合蛋白和/或标记的复合物以及用于产生这种分离的细胞靶向递送系统的方法及其用途用于治疗诊断的系统，特别是用于癌症特别是转移性癌症的诊断，特别是用于癌症治疗。

38. 发明申请

WO2013170170A3 COMPOSITIONS AND METHODS FOR GENE THERAPY 审中-公开
标题翻译：用于基因治疗的组合物和方法
公开(公告)号：WO2013170170A3
公开(公告)日：2015-06-25
申请号：PCT/US2013040577
申请日：2013-05-10
申请人： UNIV NEBRASKA
发明人： KABANOV ALEXANDER , BATRAKOVA ELENA , MAHAJAN VIVEK , HANEY MATTHEW J
IPC分类号： A61K48/00 , A61P25/16 , A61P25/28 , C12N15/00
CPC分类号： A61K48/005 , A61K35/15 , A61K38/44 , C12N5/0645 , C12N15/85
摘要： Compositions and methods for the delivery of a protein and/or nucleic acid of interest are provided.
摘要翻译：提供用于递送感兴趣的蛋白质和/或核酸的组合物和方法。

39. 发明申请

WO2015084730A1 REGULATORY MACROPHAGES AS A CELL-BASED IMMUNOMODULATORY THERAPY IN PULMONARY HYPERTENSION AND RIGHT VENTRICULAR DYSFUNCTION 审中-公开
标题翻译：作为基于细胞的免疫调节治疗肺动脉高压和右心室功能的调节作用
公开(公告)号：WO2015084730A1
公开(公告)日：2015-06-11
申请号：PCT/US2014/067940
申请日：2014-12-01
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： SCHREPFER, Sonja
IPC分类号： C12N5/0786
CPC分类号： A61K35/15 , C12N5/0645 , C12N2501/165 , C12N2501/22 , C12N2501/24
摘要： Methods and compositions are provided for preventing and treating pulmonary hypertension (PH) and right ventricular (RV) dysfunction. Aspects of the methods include administering to an individual having PH or at risk of developing PH a cell composition that is enriched for regulatory macrophages (Mregs). Also provided are systems, reagents, and kits that find use in practicing the subject methods.
摘要翻译：提供了用于预防和治疗肺动脉高压（PH）和右心室（RV）功能障碍的方法和组合物。方法的方面包括向具有PH的个体施用或在发展PH的细胞组合物富含调节性巨噬细胞（Mregs）的风险中。还提供了用于实践主题方法的系统，试剂和试剂盒。

40. 发明申请

WO2014153089A1 CD14+ CELL COMPOSITIONS AND METHODS OF USING SAME 审中-公开
标题翻译： CD14 +细胞组合物及其使用方法
公开(公告)号：WO2014153089A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/029005
申请日：2014-03-14
申请人： AASTROM BIOSCIENCES, INC.
发明人： LEDFORD, Kelly , BARTEL, Ronnda, L. , ZEIGLER, Frank
IPC分类号： C12N5/0786 , A61K35/28 , C12N5/071 , A61P9/10 , C12N5/0775
CPC分类号： C12N5/0645 , A61K35/14 , A61K35/28 , A61K35/51 , A61K35/545 , C12N5/0663 , C12N5/0669
摘要： The present invention provides CD14 + cell compositions and methods of using same in treating disorders, such as inflammatory disorders, such as atherosclerosis and cardiovascular disease.
摘要翻译：本发明提供了CD14 +细胞组合物及其在治疗诸如动脉粥样硬化和心血管疾病等炎症性疾病的疾病中的应用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式